Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (Axitinib Implant) in Subjects With Neovascular Age-Related Macular Degeneration

Running, not enrolling · Phase 3

Conditions studied: Neovascular Age-Related Macular Degeneration

In brief

Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (axitinib implant) in Subjects with Neovascular Age-Related Macular Degeneration

Key facts

Study ID
NCT06223958
Run by
Ocular Therapeutix, Inc.
People needed
344
Starts
2024-01-29
Expected to finish
2027-09-27
Last updated by the study team
2025-04-18

Who can join

Age: 50 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.